Pituitary adrenocorticotropin (ACTH) drives adrenal glucocorticoid (cortisol) pulses via a time-delayed asymptotic dose-response process. To test the postulate that ACTH stimulates cortisol secretion dynamically (unequally during the initiation and termination of a cortisol secretory burst), a mathematical formalism was developed in which doseresponse hysteretic shifts were allowed, but not required, within the time evolution of ACTH-cortisol pulse pairs. A dual-waveform deconvolution model was used to quantify cortisol secretion rates and reconstruct ACTH concentration profiles in 28 healthy adults previously sampled every 10 min for 24 hr in the unstressed state (8,120 measurements). ACTH concentration-cortisol secretion dose-response functions were then estimated in each subject (i) without hysteresis (base model), and with allowances for possible hystereses in (ii) ACTH potency (iii) adrenal sensitivity and (iv) ACTH efficacy. Model residual error was 40% lower in the potency and sensitivity models and 20% lower in the efficacy model than in the base model (P < 0.001). Mean time shifts for inferable hysteretic inflection were model-independent, viz., grand mean (95% 
Introduction
Physiological systems maintain homeostasis by reciprocal feedback (inhibitory) and feedforward (stimulatory) interactions among critical regulatory nodes (4) . Typical examples include the cardiovascular-baroreceptor, respiratory-chemoreceptor, and diverse neuroendocrine systems. Intermittent time-delimited neuroendocrine signal exchange mediates adaptations in reproductive, metabolic, growth-related and stressactivated axes (39). Local and blood-borne signals in turn act via implicit nonlinear dose-response functions, which transduce repeated incremental adjustments toward physiological optima (18; 38) . Homeostatic control in biological networks is viewed as proceeding via such time-delayed, nonlinear, asymptotic adjustments to varying internal and external signals (14; 15) .
Recent investigations in neuroendocrine ensembles suggest that finite random (stochastic) variability exists in biological parameters, beyond de facto imprecision in experimental measurements (13; 14; 16) . Biological variability may arise from nonuniformities in gene expression, glandular secretion, circulatory distribution (advection and diffusion), and fractional elimination (metabolism and biotransformation) of hormones, ligands, metabolites and effectors (3; 27; 34; 38) . In addition, both the amplitude and the timing of successive secretory bursts is episodic and uncorrelated, typical of a random renewal process (14; 15) .
A plausible contributor to inferably stochastic pulse-to-pulse variations would be shortterm random variability in effector potency, efficacy or target-gland sensitivity. Indeed, in principle, seemingly random variability in serial secretory-burst size might reflect cycles of deterministic (biologically specified) response desensitization and/or 6 resensitization occurring within or between consecutive secretory bursts. If so, an effector and target gland-selective time interval (or range of intervals) should exist within which hypothesized down-or upregulation evolves. Physiological cycles of reversible response suppression or enhancement could be consistent with a wide repertoire of other pharmacological observations in vitro and in vivo (1; 2; 10; 26; 32).
The present analyses introduce a quantitative platform for interrogating paired pulse trains for possible (mathematically estimable) cycles of dose-dependent downregulation and/or upregulation during the time evolution of individual pulses. The outcomes suggest a novel mode of dynamic signal regulation and integration.
Methods

Human subjects
Conventional cross-correlation, approximate entropy, and dose-response evaluation of these ACTH and cortisol time series were reported earlier (16; 30) . The present analyses of these archival data do not overlap with earlier outcomes or methods.
Briefly, 28 volunteers participated in the study (13 Volunteers were admitted to the Leiden Study Unit for overnight adaptation before undergoing frequent blood sampling beginning at 0900 hr the next day (30) . Blood was 7 collected every 10 min for 24 hr into ice-cold siliconized tubes containing EDTA (ACTH) or heparin (cortisol), centrifuged in the cold, and frozen within 30 min of collection, as described (30) .
Laboratory assays
Plasma ACTH concentrations were quantified in duplicate as described originally using an immunoradiometric assay [Nichols Diagnostics Institute (San Clemente, CA)] (30). Plasma cortisol was measured by RIA [Sorin Biomedica, Milan, Italy] (30).
Overview of analytical formulation
The analytical objective was to estimate possible cycles of in vivo desensitization (or resensitization) associated with the stimulus-response (feedforward) relationship mediating pulsatile ACTH concentration-dependent drive of time-delayed cortisol secretion. This has never been accomplished using these archival (or any other) data sets. The core model equations, which were developed earlier (14; 15), together embody stochastic pulse timing (two-parameter Weibull renewal process); admixed basal and pulsatile secretion; hormone and subject-specific biexponential elimination kinetics; a flexible (three-parameter generalized Gamma distribution) secretory-burst waveform or shape; random-effects on successive hormone secretory-burst mass; and, experimental uncertainty due to sample withdrawal, processing and assay (15; 16) . To optimize deconvolution analysis, the model allowed for (but did not require) two secretory-burst shapes (waveforms or psi functions), each expressed in an exclusive continuous time window in the 24-hr sampling period, as described earlier for another data set (17) . Key new features implemented in the present framework are presented in the Appendix, and highlighted below. 8 
Nonlinear effector-response function
The core model is a four-parameter logistic function relating time-varying agonist concentrations to delayed glandular secretion rates in the presence of finite stochastic inputs (random perturbations) (3; 14) . Specific dose-response properties are defined by the following parameters: (i) efficacy (asymptotically projected maximal ACTHstimulated cortisol secretion rate, nmol/L/min); (ii) potency (an exponential measure related inversely to the ACTH concentration driving one half-maximal ACTH secretion, EC 50 ); (iii) sensitivity (maximal positive slope of the ACTH-cortisol dose-response relationship); and (iv) basal (nonpulsatile) cortisol secretion (15; 16) . The innovation is to extend this structure to allow for three possible types of dose-response hystereses models, comprising possible intrapulse hysteresis-like shifts in potency, sensitivity or efficacy. Hysteresis was defined here as an effector-response dynamic, in which initial and delayed stimulation parameters over time within any given pulse differ with respect to any one of potency, sensitivity or efficacy: As a first step, ACTH and cortisol concentration-time series were deconvolved via the dual-waveform secretory-burst model (16; 17) . The unit-area normalized shape of secretory bursts (plot of rate of secretion over time) was permitted to differ in the day 10 and night, thus constituting a dual-waveform model of secretion. Two changepoint times were estimated to demarcate onset of the day and onset of the nighttime waveforms within each 24-hr pulse train (as discussed fully in (17) . Table 1 ].
Parameter estimates in the 3 hystereses models were compared by ANCOVA. Mean basal (nonpulsatile) cortisol secretion was about 6-fold lower in the efficacy hysteresis construct than in the other 3 models (row 4, Table 1 (16) . In the potency hysteresis construct, initial and delayed EC 50 's were 9.4 and 54 ng/L (P < 0.001 by Tukey's test). The initial EC 50 (8.9 ng/L) in the sensitivity model was similar to, but the delayed EC 50 (123 ng/L) was markedly higher 12 than, that in the sensitivity, efficacy or no-hysteresis models (P < 0.001). The EC 50 in the efficacy construct (10 ng/L) did not differ from that in the no-hysteresis construct (Table 1) .
Exploratory regressions on age or BMI revealed a strongly negative correlation between age and downregulated ACTH efficacy in the efficacy-shift model (P = 0.0032, 
Discussion
The stress pituitary-adrenal feedforward (stimulatory) interface was utilized as a prototypic dose-response connection in vivo to examine three complementary models of pulsatile dynamics of effector-response coupling using an archival data set (16; 30).
The potency and sensitivity downregulation constructs both achieved a 40% reduction of mean model residual error compared with a non-hysteresis formulation, and the efficacy downregulation model a 20% reduction (P < 0.001 model contrasts). The mathematical framework so developed introduces a means to assess short-term downregulation or upregulation within individual effector-response pulse pairs. General applicability of the new analytical models was ensured by permitting either downregulation (inhibition) or upregulation (potentiation) of the dose-response process on a short time scale estimated simultaneously. According to this framework, estimated ACTH-cortisol dose-response downregulation shifts occur at a relatively consistent delay of 22 min after the onset of an adrenal cortisol secretory-burst response to a pituitary ACTH concentration pulse. The geometric mean delay of < 25 min (Table 1) indicates that the three models predict rather dramatic changes within the timespan of Physiological significance of adrenal-response downregulation in the human is inferable, inasmuch as a patient harboring a rare mutation of the cytoplasmic tail of the ACTH receptor manifested Cushing syndrome due to constitutively elevated cortisol 14 secretion. The latter was associated with impaired desensitization of the transfected mutant ACTH receptor (35) . In the present analyses, age was associated with marked efficacy downregulation [ Figure 6 ]. The mechanism mediating this effect is not known, and the finding should be confirmed in longitudinal studies.
An important conceptual implication of agonist-response adaptations on short time scales is that previously presumed stochastic variability may be further partitioned into an admixture of deterministic (dose-response) downregulation and stochastic (random effects on burst mass) processes. From a deterministic (causal) vantage, rapid effectorresponse adaptations are putatively mediated by way of membrane ion channels and/or short-lived phosphorylation and phosphatase reactions (6; 7; 12; 22; 25) . To the degree that deterministic and stochastic mechanisms are quantifiable validly and reliably, their inclusion in models should make the overall evaluation of interlinked parameters more realistic and reproducible.
The generality of rapid pulsatile autoregulation of dose-response connections in other biological systems is not yet known. However, agonist-selective downregulation or upregulation within the interval of an individual pulse would offer a plausible explanation for attenuation of LH secretion by high-frequency GnRH pulses, and conversely for augmentation of hepatic IGF-I synthesis by high-frequency GH pulses (9) . Such dynamics are not shared by FSH responses to rapid GnRH pulses (37) or muscle IGF-I responses to rapid GH pulses, thus suggesting selectivity of signaling-pathway and target-organ adaptations (11; 39).
Perspectives
To our knowledge, the ACTH-cortisol dose-response nexus represents the first , where the numbers of pulses are m C and m A . The pulse times and number of pulses are to be estimated. Also, in previous modeling it was shown that there are day-night differences in the waveform of secretion for both cortisol and ACTH (17) . A unit area-normalized rate of secretion over time (waveform) is described by a 3-parameter generalized Gamma density, one for day (D) and one for night (N). The day-night separation is estimated, with day containing the interval: [φ 1 ,φ 2 ]. For r= cortisol (C), ACTH (A), the waveforms are:
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The secretion rates are then given as follows. Each secretory-burst mass is described as a linear function of the preceding interpulse interval (
) plus a random effect (A). The latter allows for variation in successive burst size, which is not explicitly modeled by a linear function:
If the fast and slow rates of elimination, for r=C,A, are denoted as: α r
and α r
, with fractions: a r and 1 − a r , then the resulting concentrations are:
Finally, what are then observed are the concentrations with measurement error:
Let θ r , for r=C,A, denote parameters for the cortisol and the ACTH models. 
This calculation involves the conditional expectations of the random effects, conditioned on the observed concentrations. Once these are obtained, one can then calculate the model fits, viz., the predicted concentrations. That is the fits are obtained by a convolution (expressions (3)- (4)) using the estimated secretion rates (expression (6)) and the estimated biexponential kinetics. The result is the predicted (reconvolved) concentrations:
,…,n; r=C, A. The results of the above (first step) are: (i) reconvolved ACTH concentrations:ˆ Y A ,i , i=1,…,n, expression (7), which constitute the ACTH feedforward signal on cortisol secretion; and (ii) estimated cortisol secretion rates: ˆ Z C ,i , i=1,…,n, expression (6) .
These are the core elements used for the second step: estimation of the dose-response In order to allow for desensitization of a cortisol response, an allowance for change in the response mechanism, specifically a possible mid-pulse shift in the dose response, is included (Figure 3, middle row) . That is, for an amount of time M AonC (a parameter to be estimated) following the onset of a cortisol pulse, one dose-response curve is followed; after that time, there is a shift to a new dose-response curve to which the ACTH feedforward signal F A (t) also applies. Specifically, three models of the doseresponse change are considered. They represent, respectively, the change in doseresponse via a shift in potency, a shift in sensitivity, and a shift in efficacy.
Model 1:
Half-Maximally Effective Stimulus Concentration (ACTH Potency):
Model 2: Dose-Response Slope (Adrenal Sensitivity):
Model 3: Asymptotic Maximum (ACTH Efficacy):
In Figure 3 , the three columns (left, middle, right) represent the applications of the above three models for the same subject as in Figure 2 . 
